Robust CAR T‐cell expansion and superior outcomes in DLBCL patients in complete response at infusion
Open Access
- 25 May 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 207 (1) , 180-188
Abstract
Summary: Historically, the presence of measurable disease has been considered essential to stimulate CAR T‐cell expansion and persistence. However, the kinetics of CAR T cells in patients achieving complete response (CR) before infusion remain poorly understood. This study aimed to evaluate the outcomes and CAR T‐cell kinetics in relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) patients stratified by pre‐infusion disease status. In this retrospective analysis of 87 patients treated at a single institution, 23 (26.4%) were in CR and 64 (73.6%) were in non‐CR prior to CAR T‐cell infusion. Patients in CR exhibited significantly better progression‐free survival (PFS) and overall survival compared to non‐CR patients. Peripheral blood CAR T‐cell kinetics, including the proportion and absolute counts of CAR T cells, CD4+ CAR T cells and CD8+ CART cells, showed no significant differences between CR and non‐CR groups. These findings were consistent across different CAR T‐cell products, whether 4‐1BB‐ or CD28‐based. Moreover, an analysis of patients achieving complete metabolic response (CMR) by PET‐CT confirmed comparable CAR T‐cell expansion and persistence in both CMR and non‐CMR patients. Our findings demonstrate that CAR T‐cell therapy achieves robust expansion and favourable survival outcomes in CR patients, even in the absence of measurable disease.Keywords
Funding Information
- Japan Society for the Promotion of Science (23K15323)
This publication has 27 references indexed in Scilit:
- Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysisLeukemia, 2024
- Cytokine release syndrome and associated neurotoxicity in cancer immunotherapyNature Reviews Immunology, 2021
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Sex differences in immune responses that underlie COVID-19 disease outcomesNature, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Sex differences in immune responsesNature Reviews Immunology, 2016
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T CellsImmunity, 2016
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012